Iovance Biotherapeutics, Inc. (IOVA) Cash Flow Statement
Iovance Biotherapeutics, Inc. (IOVA) generated -$264.2M of operating cash flow over the twelve months to 2026-06-30, spent $32.2M on capital expenditure and had free cash flow of -$296.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IOVAIovance Biotherapeutics, Inc.Follow IOVA — free
—
Price chart with a free account
- Market cap
- 6.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -361.8 | -353.0 | -302.4 | -264.2 | |
| Capital expenditure | 22.3 | 11.1 | 33.8 | -32.2 | |
| Free cash flow | -384.1 | -364.0 | -336.2 | -296.4 | |
| Stock-based compensation | 62.6 | 109.6 | 61.6 | — |
USD millions · SEC XBRL
Iovance Biotherapeutics, Inc. — questions
- What is Iovance Biotherapeutics, Inc.'s operating cash flow?
- -$264.2M over the twelve months to 2026-06-30.
- How much does Iovance Biotherapeutics, Inc. spend on capital expenditure?
- $32.2M over the twelve months to 2026-06-30.
- What is Iovance Biotherapeutics, Inc.'s free cash flow?
- -$296.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Iovance Biotherapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.